Predicate Device Selection Strategy: How to Choose a Predicate That Survives FDA Scrutiny

Your 510(k) Is Only as Strong as Your Predicate

If you have spent any time preparing a 510(k) submission, you already know that predicate selection is not a formality. It is the architectural foundation of your entire substantial equivalence argument. Choose the wrong predicate, and FDA will issue an Additional Information request that stalls your clearance by months, or worse, a Not Substantially Equivalent determination that sends you back to square one.

At ADB Consulting and CRO Inc., we have guided medical device startups and established companies through hundreds of 510(k) submissions. The single most common source of avoidable delays we see is a predicate selected too quickly, too casually, or with an eye toward convenience rather than defensibility. This post lays out the strategic framework we use to select predicates that survive FDA scrutiny.

Understand What FDA Is Actually Looking For

Under Section 513(i) of the Federal Food, Drug, and Cosmetic Act, a device is substantially equivalent to a predicate if it has the same intended use and either the same technological characteristics, or different technological characteristics that do not raise new questions of safety and effectiveness. That sounds straightforward. In practice, FDA reviewers are trained to probe every gap in your argument.

FDA's guidance document Appropriate Use of Voluntary Consensus Standards in Premarket Submissions (2018) and the foundational The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications (2014) lay out the decision-making framework reviewers follow. You should know this framework better than the reviewer assigned to your file.

Start With Intended Use, Not Product Category

A mistake we see constantly is founders searching 510(k) databases by device type or product code before they have locked down their intended use statement. The intended use drives everything. Before you open the FDA 510(k) database or a third-party tool, write a precise, scope-limited intended use statement. Then search for predicates whose cleared intended use overlaps as closely as possible with yours.

A predicate with a broader intended use can create problems. FDA may question whether your narrower device truly shares the same intended use, or they may hold you to performance standards designed for a device with a wider clinical scope. A predicate with a materially different intended use is simply disqualifying.

The Four Criteria for a Defensible Predicate

Once you have a candidate list, evaluate each predicate against these four criteria before committing to your submission strategy:

• Cleared intended use alignment: The predicate must have a cleared intended use that is the same as, or substantially overlapping with, yours. Review the original 510(k) Summary or Statement, not just the product description in the 510(k) database.
• Technological characteristics comparability: Under 21 CFR 807.87(f), you must describe how your device compares to the predicate. If your technological characteristics differ, you need a clear, data-supported argument that the differences do not raise new safety or effectiveness questions. Do not assume FDA will accept a narrative argument alone.
• Current regulatory status: A predicate that has been recalled, has an open Class II or Class III recall, or has been the subject of a 522 postmarket surveillance order introduces risk. FDA is not prohibited from accepting such predicates, but reviewers will scrutinize your submission more closely.
• Special controls applicability: If your predicate device type carries special controls under 21 CFR Part 880, 870, or other device-specific sections, those controls apply to your device as well. Make sure you can meet them before selecting that predicate.

The Split Predicate Question

Sometimes a single predicate does not cover all the features of your device. FDA has long permitted the use of multiple predicates, a strategy sometimes called a split predicate approach. However, FDA's 2014 510(k) Program guidance is clear that you cannot use one predicate for intended use and a different predicate for technological characteristics unless both predicates have the same intended use as your device. Misapplying the split predicate approach is one of the fastest ways to receive a Refuse to Accept notification under FDA's RTA checklist.

De Novo as a Strategic Alternative

If your search yields no suitable predicate, do not force a weak one. A poorly chosen predicate invites an NSE determination and may actually delay you longer than a well-prepared De Novo request under 21 CFR 860.257. De Novo establishes a new classification with special controls and creates a cleared device that itself becomes a predicate for future market entrants. For genuinely novel low-to-moderate risk devices, De Novo is often the strategically superior path.

Document Your Selection Rationale Before You Submit

One practice we implement for every client is a formal predicate selection memo prepared before the 510(k) is drafted. This memo documents why candidate predicates were accepted or rejected, the intended use comparison analysis, and the technological characteristics delta assessment. If FDA asks questions during review, you have a defensible, contemporaneous record. If your submission team changes, institutional knowledge does not walk out the door.

Work With Experts Who Know What Reviewers Are Looking For

Predicate selection is part science, part strategy, and part institutional knowledge of how specific FDA review divisions interpret substantial equivalence. Getting it right before you submit is exponentially less expensive than responding to AI requests or resubmitting after an NSE.

ADB Consulting and CRO Inc. brings deep, submission-level expertise to predicate strategy, 510(k) preparation, and FDA communications. Whether you are preparing your first submission or rebuilding a strategy after a setback, we are ready to help you move forward with confidence.

Book a free discovery call with Andre Butler and the ADB Consulting team at adbccro.com. Let us review your predicate strategy before FDA does.